{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:56:09Z","timestamp":1789145769451,"version":"build-2803163510"},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Autoimmune bullous diseases are associated with high morbidity and mortality. Traditionally, systemic corticosteroids and conventional immunosuppressive agents have been the mainstay of treatment, but their broad immunosuppressive effects and long-term complications have prompted the exploration of newer more targeted therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>This review explores the evolving landscape of therapeutic options for immunobullous diseases, with a particular focus on pemphigus, bullous pemphigoid (BP), and mucous membrane pemphigoid, by searching PubMed, clinicaltrials.gov, and Cochrane databases for published literature from 2014 to 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results\/Discussion:<\/jats:title>\n                    <jats:p>We discuss emerging treatments for pemphigus such as B cell modulatory drugs, anti-inflammatory drugs, those inhibiting autoantibody half-life or blister-inducing activity, and stem cell therapy, while offering insights into the level of evidence, potential benefits, and limitations of each approach. The role of biologics and novel therapies like rituximab, omalizumab, and dupilumab in reshaping the management of BP is also discussed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The article highlights the need for further research, clinical trials, and comparative studies to determine the most effective and safest treatment options for patients with immunobullous diseases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/idoj.idoj_740_23","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T08:28:59Z","timestamp":1725006539000},"page":"758-769","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Updates on the Management of Autoimmune Bullous Diseases"],"prefix":"10.4103","volume":"15","author":[{"given":"Rajat","family":"Choudhary","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujay","family":"Khandpur","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,8,30]]},"reference":[{"key":"R2-20240830","first-page":"236","article-title":"Rituximab in pemphigus vulgaris - Standard operating procedure","volume":"4","author":"Ajithkumar","year":"2022","journal-title":"J Skin Sex Transm Dis"},{"key":"R3-20240830","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.25039","article-title":"Good and bad memories following rituximab therapy","volume":"62","author":"St Clair","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R4-20240830","doi-asserted-by":"crossref","first-page":"457993","DOI":"10.3389\/fimmu.2019.01418","article-title":"Pemphigus: Current and future therapeutic strategies","volume":"10","author":"Didona","year":"2019","journal-title":"Front Immunol"},{"key":"R5-20240830","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1182\/blood-2014-10-569244","article-title":"Fc\u03b3-receptor-mediated trogocytosis impacts mAb-based therapies: Historical precedence and recent developments","volume":"125","author":"Taylor","year":"2015","journal-title":"Blood"},{"key":"R6-20240830","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1111\/ced.15213","article-title":"Comparison of the efficacy and cost-effectiveness of an immunologically targeted low-dose rituximab protocol with the conventional rheumatoid arthritis protocol in severe pemphigus","volume":"47","author":"Singh","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"R7-20240830","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41598-017-17934-6","article-title":"Single, very low rituximab doses in healthy volunteers -a pilot and a randomized trial: Implications for dosing and biosimilarity testing","volume":"8","author":"Schoergenhofer","year":"2018","journal-title":"Sci Rep"},{"key":"R8-20240830","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/bjd.20819","article-title":"Ultralow-dose rituximab in pemphigus: A single-centre experience","volume":"186","author":"Simpson","year":"2022","journal-title":"Br J Dermatol"},{"key":"R9-20240830","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1080\/14712598.2020.1727440","article-title":"Ultra-low dose rituximab for refractory pemghigus vulgaris: A pilot study","volume":"20","author":"Russo","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"R10-20240830","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1001\/jamadermatol.2014.1939","article-title":"Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris","volume":"150","author":"Ellebrecht","year":"2014","journal-title":"JAMA Dermatol"},{"key":"R11-20240830","first-page":"1338","article-title":"Successful Treatment of pemphigus vulgaris with ofatumumab","volume":"17","author":"Rapp","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"R13-20240830","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jdcr.2022.07.011","article-title":"Obinutuzumab in a patient with chronic lymphocytic leukemia-associated paraneoplastic pemphigus","volume":"27","author":"Freund","year":"2022","journal-title":"JAAD Case Rep"},{"key":"R14-20240830","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/art.40425","article-title":"Efficacy of epratuzumab, an anti-CD22 monoclonal igg antibody, in systemic lupus erythematosus patients with associated sj\u00f6gren's syndrome: post hoc analyses from the EMBODY trials","volume":"70","author":"Gottenberg","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"R15-20240830","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/ijd.16363","article-title":"Elevated serum level of B-cell activating factor (BAFF) after rituximab therapy in pemphigus vulgaris patients suggests a possible therapeutic efficacy of B-cell depletion therapies combined with anti-BAFF agents","volume":"62","author":"Daneshvar","year":"2023","journal-title":"Int J Dermatol"},{"key":"R16-20240830","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/annrheumdis-2018-214720","article-title":"Treatment of primary Sj\u00f6gren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity","volume":"78","author":"D\u00f6rner","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"R18-20240830","doi-asserted-by":"crossref","first-page":"708071","DOI":"10.3389\/fmed.2021.708071","article-title":"Bruton Tyrosine Kinase Inhibition and its role as an emerging treatment in pemphigus","volume":"10","author":"Patsatsi","year":"2021","journal-title":"Front Med (Lausanne)."},{"key":"R19-20240830","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.1182\/bloodadvances.2022007793","article-title":"The dosing of ibrutinib and related Bruton's tyrosine kinase inhibitors: Eliminating the use of brute force","volume":"6","author":"Ratain","year":"2022","journal-title":"Blood Adv"},{"key":"R20-20240830","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1111\/ajd.12615","article-title":"Successful use of Bruton's kinase inhibitor, ibrutinib, to control paraneoplastic pemphigus in a patient with paraneoplastic autoimmune multiorgan syndrome and chronic lymphocytic leukaemia","volume":"58","author":"Lee","year":"2017","journal-title":"Australas J Dermatol"},{"key":"R21-20240830","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/bjd.20431","article-title":"Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: The phase II BELIEVE study*","volume":"185","author":"Murrell","year":"2021","journal-title":"Br J Dermatol"},{"key":"R23-20240830","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1001\/jama.2017.15218","article-title":"2017 undefined. FDA approval of tisagenlecleucel: Promise and complexities of a $475 000 cancer drug","volume":"318","author":"Bach","year":"2017","journal-title":"JAMA"},{"key":"R24-20240830","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"R25-20240830","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.1172\/JCI138416","article-title":"Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris","volume":"130","author":"Lee","year":"2020","journal-title":"J Clin Invest"},{"key":"R26-20240830","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1016\/j.jid.2021.06.035","article-title":"Targeting the FcRn: A novel approach to the treatment of pemphigus","volume":"141","author":"Nelson","year":"2021","journal-title":"J Invest Dermatol"},{"key":"R27-20240830","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/bjd.20782","article-title":"Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: A phase II multicentre, open-label feasibility trial","volume":"186","author":"Goebeler","year":"2022","journal-title":"Br J Dermatol"},{"key":"R28-20240830","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1016\/j.jid.2021.04.031","article-title":"Safety, tolerability, and activity of ALXN1830 targeting the neonatal Fc receptor in chronic pemphigus","volume":"141","author":"Werth","year":"2021","journal-title":"J Invest Dermatol"},{"key":"R29-20240830","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/jdv.16752","article-title":"Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the European Academy of Dermatology and Venereology (EADV)","volume":"34","author":"Joly","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R30-20240830","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/bjd.15930","article-title":"British Association of Dermatologists'guidelines for the management of pemphigus vulgaris 2017","volume":"177","author":"Harman","year":"2017","journal-title":"Br J Dermatol"},{"key":"R31-20240830","first-page":"ljad489","article-title":"Efficacy and safety of adjuvant immunoadsorption in pemphigus vulgaris and pemphigus foliaceus (IA-Pem Study): A multicentrerandomised controlled trial","author":"van Beek","year":"2023","journal-title":"Br J Dermatol"},{"key":"R32-20240830","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3109\/08916934.2011.606452","article-title":"Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: An update","volume":"45","author":"Czernik","year":"2012","journal-title":"Autoimmunity"},{"key":"R33-20240830","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jaci.2011.01.061","article-title":"Association of anti-IgA antibodies with adverse reactions to \u03b3-globulin infusion","volume":"128","author":"Rachid","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"R34-20240830","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1056\/NEJMoa062930","article-title":"Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin","volume":"355","author":"Ahmed","year":"2006","journal-title":"N Engl J Med"},{"key":"R35-20240830","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cyto.2015.09.017","article-title":"Interleukin 4 inhibition as a potential therapeutic in pemphigus","volume":"77","author":"Tavakolpour","year":"2016","journal-title":"Cytokine"},{"key":"R36-20240830","doi-asserted-by":"crossref","first-page":"825796","DOI":"10.3389\/fimmu.2022.825796","article-title":"A novel combined use of dupilumab for treatment of aggressive refractory pemphigus vulgaris complicated with pulmonary tuberculosis: a case report and the RNA-seq analysis","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"key":"R37-20240830","doi-asserted-by":"crossref","first-page":"e16679","DOI":"10.1016\/j.heliyon.2023.e16679","article-title":"Targeting therapy in pemphigus: Where are we now and where are we going?","volume":"9","author":"Abulikemu","year":"2023","journal-title":"Heliyon"},{"key":"R38-20240830","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1001\/archderm.140.3.327","article-title":"Pemphigus vulgaris acantholysis ameliorated by cholinergic agonists","volume":"140","author":"Nguyen","year":"2004","journal-title":"Arch Dermatol"},{"key":"R39-20240830","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1087-0024.2004.00826.x","article-title":"New approaches to the treatment of pemphigus","volume":"9","author":"Grando","year":"2004","journal-title":"J Invest Dermatol Symp Proc"},{"key":"R40-20240830","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1365-4632.2006.02766.x","article-title":"Healing effect of pilocarpine gel 4% on skin lesions of pemphigus vulgaris","volume":"45","author":"Iraji","year":"2006","journal-title":"Int J Dermatol"},{"key":"R41-20240830","first-page":"e15449","article-title":"Effectiveness of topical pilocarpine in refractory oral lesions of pemphigus vulgaris: Results from an open-label, prospective, pilot study","author":"De","year":"2022","journal-title":"Dermatol Ther March"},{"key":"R42-20240830","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4103\/0019-5154.92667","article-title":"Allogenic hematopoietic stem cell transplantation in pemphigus vulgaris: A single-center experience","volume":"57","author":"Vanikar","year":"2012","journal-title":"Indian J Dermatol"},{"key":"R43-20240830","first-page":"2867","article-title":"Rituximab, omalizumab, and dupilumab treatment outcomes in bullous pemphigoid: a systematic review","volume":"13","author":"Cao","year":"2022","journal-title":"Front Immunol"},{"key":"R44-20240830","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/ckj\/sfx038","article-title":"Infectious complications of rituximab therapy in renal disease","volume":"10","author":"Nixon","year":"2017","journal-title":"Clin Kidney J"},{"key":"R45-20240830","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/jdv.18220","article-title":"Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)","volume":"36","author":"Borradori","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R46-20240830","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1177\/12034754221089267","article-title":"Omalizumab for the treatment of bullous pemphigoid: a systematic review of efficacy and safety","volume":"26","author":"D'Aguanno","year":"2022","journal-title":"J Cutan Med Surg"},{"key":"R48-20240830","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/all.13950","article-title":"Mepolizumab failed to affect bullous pemphigoid: A randomized, placebo-controlled, double-blind phase 2 pilot study","volume":"75","author":"Simon","year":"2020","journal-title":"Allergy"},{"key":"R49-20240830","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13223-021-00619-1","article-title":"Successful induction treatment of bullous pemphigoid using reslizumab: A case report","volume":"17","author":"Rhyou","year":"2021","journal-title":"Allergy Asthma Clin Immunol"},{"key":"R53-20240830","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1111\/ajd.13803","article-title":"Successful secukinumab treatment of active bullous pemphigoid and chronic severe psoriasis: A case report","volume":"63","author":"Yun","year":"2022","journal-title":"Australas J Dermatol"},{"key":"R54-20240830","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1111\/1346-8138.14760","article-title":"Secukinumab decreased circulating anti-BP180-NC16a autoantibodies in a patient with coexisting psoriasis vulgaris and bullous pemphigoid","volume":"46","author":"Kamata","year":"2019","journal-title":"J Dermatol"},{"key":"R58-20240830","doi-asserted-by":"crossref","first-page":"e15754","DOI":"10.1111\/dth.15754","article-title":"Concurrent bullous pemphigoid and plaque psoriasis successfully treated with Janus kinase inhibitor Baricitinib","volume":"35","author":"Xiao","year":"2022","journal-title":"Dermatol Ther"},{"key":"R59-20240830","doi-asserted-by":"crossref","first-page":"718073","DOI":"10.3389\/fimmu.2021.718073","article-title":"Emerging biomarkers and therapeutic strategies for refractory bullous pemphigoid","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Immunol"},{"key":"R60-20240830","doi-asserted-by":"crossref","first-page":"604","DOI":"10.2340\/00015555-1142","article-title":"Oral mucous membrane pemphigoid: complete response to topical tacrolimus","volume":"91","author":"Lee","year":"2011","journal-title":"Acta Derm Venereol"},{"key":"R61-20240830","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1684\/ejd.2021.4132","article-title":"Management of mucous membrane pemphigoid: A literature review and update","volume":"32","author":"Alrashdan","year":"2022","journal-title":"Eur J Dermatol"},{"key":"R62-20240830","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1001\/jamaophthalmol.2018.3789","article-title":"Treatment of mucous membrane pemphigoid with janus kinase inhibitor baricitinib","volume":"136","author":"Sarny","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"R63-20240830","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jdcr.2017.08.005","article-title":"Successful treatment of mucous membrane pemphigoid with bortezomib","volume":"4","author":"Saeed","year":"2018","journal-title":"JAAD Case Rep"},{"key":"R64-20240830","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1001\/archderm.142.11.1457","article-title":"Successful treatment of mucous membrane pemphigoid with etanercept in 3 patients","volume":"142","author":"Canizares","year":"2006","journal-title":"Arch Dermatol"}],"container-title":["Indian Dermatology Online Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.idoj_740_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:15:45Z","timestamp":1787771745000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.idoj_740_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/idoj.idoj_740_23","relation":{},"ISSN":["2229-5178","2249-5673"],"issn-type":[{"value":"2229-5178","type":"print"},{"value":"2249-5673","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,30]]},"assertion":[{"value":"2023-09-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}